1. Primary prevention: The unsettling question

   • John C. LaRosa

   Invited Commentary Pages: 1 - 2

2. Web alert

   Announcement Pages: 3 - 3

3. Clinical trials report

   • Michael Clearfield

   OriginalPaper Pages: 7 - 10

4. Results of new statin trials: Should the low-density lipoprotein cholesterol treatment guidelines be revised?

   • Allison M. J. Ross
   • Theodore G. Ganiats

   OriginalPaper Pages: 11 - 16

5. Statin use in the metabolic syndrome

   • Justin B. Lundbye
   • Paul D. Thompson

   OriginalPaper Pages: 17 - 21

6. Utility of statin therapy using high-sensitivity C-reactive protein as an indicator of coronary heart disease risk

   • Vijay Nambi
   • Christie M. Ballantyne

   OriginalPaper Pages: 22 - 28

7. Rationale for combination therapy with statin drugs in the treatment of dyslipidemia

   • Benjamin J. Ansell

   OriginalPaper Pages: 29 - 33

8. Pleiotropic effects of statins: Moving beyond cholesterol control

   • Paul J. Garcia

   OriginalPaper Pages: 34 - 39

9. Inflammation as a mechanism and therapeutic target for in-stent restenosis

   • Douglas E. Drachman
   • Daniel I. Simon

   OriginalPaper Pages: 44 - 49

10. The impact of antidiabetic therapies on cardiovascular disease

    • Brandy Panunti
    • Biju Kunhiraman
    • Vivian Fonseca

    OriginalPaper Pages: 50 - 57

11. Adipocytokines: Emerging therapeutic targets

    • Yuji Matsuzawa

    OriginalPaper Pages: 58 - 62

12. Fatty acid oxidation inhibitors in the management of chronic complications of atherosclerosis

    • Clifford D. L. Folmes
    • Alexander S. Clanachan
    • Gary D. Lopaschuk

    OriginalPaper Pages: 63 - 70

13. Antioxidants and atherosclerosis: Emerging drug therapies

    • Jean-Claude Tardif

    OriginalPaper Pages: 71 - 77

14. Clinical trials report

    • Daniel Eisenberg

    OriginalPaper Pages: 78 - 78